Korro Bio’s Progress and Financial Updates
Korro Bio, Inc. ( (KRRO) ) has released its Q3 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors.
Korro to Present at the Jefferies London Healthcare Conference
A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the ...
Yahoo Finance10d
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...
Nasdaq24d
Korro Bio price target raised to $105 from $95 at RBC Capital
RBC Capital raised the firm’s price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that RNA editing data from Wave Life Sciences (WVE ...
Nasdaq24d
Korro Bio initiated with a Strong Buy at Raymond James
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...
ETF Daily News22d
Korro Bio (NASDAQ:KRRO) Price Target Raised to $105.00
Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...
ETF Daily News28d
Korro Bio, Inc. (NASDAQ:KRRO) Sees Significant Decrease in Short Interest
Shares of NASDAQ KRRO opened at $77.00 on Thursday. Korro Bio has a 12-month low of $9.15 and a 12-month high of $98.00. The stock has a fifty day moving average price of $40.45 and a 200 day ...
manilatimes10d
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and ...